Liraglutide vs Cagrilintide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Liraglutide

Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.

Full details →

Cagrilintide

Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.

Full details →

Side-by-Side Comparison

AspectLiraglutideCagrilintide
MechanismBinds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects.Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1.
Typical DosageSaxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily.Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined.
AdministrationSubcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications.Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved.
Side EffectsNausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use.Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially.
Best For

What They Have in Common

Both Liraglutide and Cagrilintide are commonly used for:

Ready to Learn More?